Wilkinson Dominic J
The Ethox Centre, University of Oxford, Oxford, UK.
Acta Paediatr. 2009 Feb;98(2):217-20. doi: 10.1111/j.1651-2227.2008.01127.x. Epub 2008 Nov 28.
Hypothermia is the first treatment for newborns with hypoxic-ischaemic encephalopathy (HIE) with consistent evidence of a reduction in the risk of death or severe disability. This paper addresses a number of ethical and practical issues faced by clinicians as cooling moves from an experimental treatment into practice. These issues are not unique to therapeutic hypothermia. They include the extrapolation of evidence from trials to clinical care, as well as the impact of hypothermia on prognosis and withdrawal of life-sustaining treatment.
Hypothermia is a promising new therapy, but further research will be necessary to help resolve some of the ethical concerns associated with its use in newborns with HIE .
低温治疗是新生儿缺氧缺血性脑病（HIE）的首要治疗方法，有一致证据表明其可降低死亡或严重残疾风险。随着低温治疗从实验性治疗转变为临床实践，本文探讨了临床医生面临的一些伦理和实际问题。这些问题并非低温治疗所独有。它们包括从试验证据外推至临床护理，以及低温治疗对预后的影响和生命维持治疗的撤除。
低温治疗是一种有前景的新疗法，但需要进一步研究以帮助解决与在HIE新生儿中使用该疗法相关的一些伦理问题。
